Generic Failure: Why 90% of ANDAs Are Rejected on the First Pass 

In this video, Nicholas Fleischer, R.Ph., Ph.D., Vice President, Clinical Pharmacology and Biopharmaceutics at The Weinberg Group, discusses why so many ANDAs are rejected and explains some of the qualities of successful generic applications.
If you have any questions about this video, or would just like to learn more about what we do, please contact us at 202.833.8077 or science@weinberggroup.com.